Mon premier blog

Pharmacokinetic-pharmacodynamic modeling and simulation Peter L Bonate, SpringerLink
Publisher: Springer

A comprehensive simulation study to assess the utility of a stage-specific pharmacokinetic-pharmacodynamic (PK-PD) model for predicting within-host parasite response was performed. 2004 Pharmacokinetics in Drug Development: Regulatory and Development Paradigms, Volume 2, AAPS Press, Arlington, VA ISBN 0-9711767-3-6; Bonate, P.L. Additionally, the company's new additions to the pharmacokinetic, pharmacodynamic, modeling, and simulation services area are Dr. Quantitative representation of the dose-concentration- response relationship should provide PK-PD simulations allow the assessment of the descriptive parameters as the functions of dose and dose rate. 2006 Pharmacokinetic-Pharmacodynamic Modeling and Simulation, . And Pharmacodynamics of Abused Drugs, CRC Press, Boca Raton, FL ISBN 978-1-4200-5458-3; Kimko, H. Joomi Lee, MS; Yangha Hwang Financial disclosure: This research was supported by the Korea National Enterprise for Clinical Trials, a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, the Republic of South Korea (A070001), and by the Pfizer Modeling & Simulation Education Center in Korea (PMECK). In Pharmacokinetic-pharmacodynamic modeling and simulation. Bonate, "Pharmacokinetic-Pharmacodynamic Modeling and Simulation" Sp ger | 2011 | ISBN: 144199484X | 651 pages | PDF | 11,1 MB. Nidal Al-Hunti, principal scientist; Dr. Pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical pharmacology to optimize drug use by designing rational dosage forms and dosage regimes. Population Pharmacokinetic/Pharmacodynamic Modeling of Clopidogrel in Korean Healthy Volunteers and Stroke Patients. Robert Bauer, vice president of pharmacometrics; Dr. Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments. This timescale was selected as indacaterol is known to have reached both pharmacodynamic and pharmacokinetic steady state by Week 2 [2].